Family

Fibroblast growth factor 23 (IPR028304)

Short name: FGF23

Family relationships

Description

Fibroblast growth factors (FGFs) [PMID: 2549857, PMID: 3072709] are a family of multifunctional proteins, often referred to as 'promiscuous growth factors' due to their diverse actions on multiple cell types [PMID: 1705486, PMID: 8760337]. The function of FGFs in developmental processes include mesoderm induction, anterior-posterior patterning, limb development, and neural induction and development. In mature tissues, they are involved in diverse processes including keratinocyte organisation and wound healing [PMID: 11276432, PMID: 23000357, PMID: 15689573, PMID: 10441498, PMID: 23108135, PMID: 23016864]. FGF involvement is critical during normal development of both vertebrates and invertebrates, and irregularities in their function leads to a range of developmental defects [PMID: 1649700, PMID: 11746231, PMID: 14745970, PMID: 8978613]. Fibroblast growth factors are heparin-binding proteins and interactions with cell-surface-associated heparan sulfate proteoglycans have been shown to be essential for FGF signal transduction. There are currently over 20 different FGF family members that have been identified in mammals, all of which are structurally related signaling molecules [PMID: 8652550, PMID: 11276432]. They exert their effects through four distinct membrane fibroblast growth factor receptors (FGFRs), FGFR1 to FGFR4 [PMID: 7583099], which belong to the tyrosine kinase superfamily.

This entry represents fibroblast growth factor 23 (FGF23), which is secreted by osteoblasts and osteoclasts [PMID: 22249518]. FGF23 acts on kidneys, where it decreases the expression of NPT2, a sodium-phosphate cotransporter in the proximal tubule [PMID: 21346724]. FGF23 is responsible for phosphate metabolism, decreasing the reabsorption and increasing excretion of phosphate [PMID: 18310961]. FGF23 is involved in the pathogenesis of three hypophosphatemic disorders; oncogenic osteomalacia (OOM), X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR). These conditions are characterised by hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum calcitriol concentrations and defective skeletal mineralisation [PMID: 11409890, PMID: 18310961, PMID: 11062477].

GO terms

Biological Process

GO:0008543 fibroblast growth factor receptor signaling pathway

Molecular Function

GO:0005104 fibroblast growth factor receptor binding

Cellular Component

GO:0005576 extracellular region

Contributing signatures

Signatures from InterPro member databases are used to construct an entry.
PANTHER